By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Molecular Insight Pharmaceuticals, Inc. 

160 Second Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-492-5554 Fax: 617-492-5664


SEARCH JOBS

Molecular Insight is a privately held, emerging biopharmaceutical company based in Cambridge, Massachusetts. The company is focused on leveraging its proprietary technology platforms to develop innovative imaging pharmaceuticals that improve the visualization and management of disease. Molecular Insight has established a strong pipeline of product candidates focused on the large markets in cardiology, infectious disease, cancer and neurology. The company's lead compound, BMIPP for the detection of ischemia, is nearing completion of multi-center Phase II clinical trials.

The company's technology platforms are producing new radiopharmaceuticals that have the potential to detect the earliest changes in the molecular biology of the cell. Specific changes in gene expression, protein expression, protein function and biochemistry provide important insights into the nature and status of disease. These new technologies also promise to offer safer, more effective and less costly imaging procedures.

Molecular Insight's management team is led by David S. Barlow, Chairman and CEO. He has more than 20 years of management experience and achievements in the biopharmaceutical industry, most recently as President of Sepracor Pharmaceuticals. John W. Babich, Ph.D., President and CSO is a leader in the field of medical imaging and nuclear medicine and formerly on the faculty of Harvard Medical School and Massachusetts General Hospital. John E. McCray, Chief Operating Officer, has more than 20 years of operations, public policy experience in the biopharmaceutical industry. The company's scientific advisory board is chaired by William C. Eckelman, Ph.D., Chief of Positron Emission Tomography at the NIH Clinical Center.

Last Updated: 02-02-2007

Key Statistics


Email: jmccray@molecularinsight.com
Ownership: Public

Web Site: Molecular Insight Pharmaceuticals, Inc.
Employees:
Symbol: MIPI
 









Company News
Progenics Pharmaceuticals, Inc. (PGNX) Acquires Molecular Insight Pharmaceuticals, Inc. (MIPI) to Expand Oncology-Focused Pipeline 1/22/2013 9:18:59 AM
Molecular Insight Pharmaceuticals, Inc. (MIPI) Announces Initiation of Phase 2 Trial for Prostate Cancer Molecular Imaging Drug 9/25/2012 9:01:29 AM
Molecular Insight Pharmaceuticals, Inc. (MIPI) Presents Clinical Oncology Data at Society of Nuclear Medicine 2012 Annual Meeting 6/14/2012 9:12:54 AM
Molecular Insight Pharmaceuticals, Inc. (MIPI) Elects a New Board of Directors 2/23/2012 8:25:35 AM
Molecular Insight Pharmaceuticals, Inc. (MIPI) Presents Human Data Demonstrating Detection of Metastatic Prostate Cancer 2/3/2012 8:26:45 AM
Molecular Insight Pharmaceuticals, Inc. (MIPI) Release: Radiopharmaceutical for Targeted Treatment of Prostate Cancer to Enter Clinical Trials 1/30/2012 9:59:40 AM
Molecular Insight Pharmaceuticals, Inc. (MIPI) Release: Radiopharmaceutical for Targeted Treatment of Prostate Cancer to Enter Clinical Trials 1/30/2012 8:32:59 AM
Molecular Insight Pharmaceuticals, Inc. (MIPI) Presents Positive Phase 1 Prostate Cancer Data at the Annual Congress of the European Association of Nuclear Medicine 10/21/2011 10:28:42 AM
Molecular Insight Pharmaceuticals, Inc. (MIPI)' Trofex Data Published in Journal of Nuclear Medicine 7/7/2011 9:14:26 AM
Molecular Insight Pharmaceuticals, Inc. (MIPI) Presents Oncology Data at Society of Nuclear Medicine 2011 Annual Meeting 6/14/2011 8:06:48 AM
12345678910...
//-->